10-K: CytoSorbents posts narrower loss; FDA path reset

CytoSorbents grew 2025 revenue 4% and improved margins but flagged going concern risks, Nasdaq noncompliance, and a reset FDA path for DrugSorb-ATR after a 2025 De Novo denial.

Summary

• Product revenue was $37.1 million for 2025, up 4.1% year over year (down 0.4% on a constant currency basis).
• Gross margin improved to 71.5% (from 69.9% in 2024); gross profit rose to $26.5 million.
• Net loss narrowed to $8.2 million (from $20.7 million in 2024); operating loss improved to $14.7 million (from $16.5 million).
• Research & development expense fell 33.2% to $5.1 million; SG&A increased 5% to $35.6 million.
• Recorded a $0.5 million restructuring charge tied to a ~10% workforce reduction and cost actions.
• Foreign currency transaction gain of $9.3 million (vs. a $4.2 million loss in 2024) materially aided the bottom line; interest expense was $2.6 million.
• Cash and cash equivalents were $6.3 million at 12/31/2025 (total cash including restricted: $7.8 million); current assets $20.6 million vs. current liabilities $9.7 million.
• Auditor included a going concern emphasis; management cites potential need for additional capital despite cost reductions.
• Long‑term debt (net) was $16.7 million; Avenue Capital facility amended on Nov 13, 2025, adding $2.5 million and extending interest‑only to Dec 31, 2026; potential further $2.5 million tranche upon FDA approval by Dec 31, 2026.
• Raised $6.25 million gross via a Jan 10, 2025 rights offering; ~1.42 million Series A warrants were exercised on Feb 24, 2025 for ~$1.6 million gross; Series B warrants expired worthless on Jun 10, 2025.
• FDA denied the DrugSorb‑ATR De Novo on Apr 25, 2025; appeal upheld denial on Aug 14, 2025 (no safety issues cited). Company will file a new De Novo after a Jan 2026 pre‑submission meeting; 150‑day review expected after resubmission.
• Health Canada issued a Notice of Refusal on Jun 26, 2025; reconsideration was withdrawn pending clearer FDA visibility.
• Nasdaq minimum bid deficiency notice received Oct 2, 2025; initial cure period to Mar 31, 2026, with an extension request filed (reverse split contemplated if needed).
• CytoSorb remains CE‑marked in the EU and distributed in 70+ countries; cumulative devices used exceed 300,000.

Sentiment

Score: 4

Explanation: StockSavvy.ai views 2025 operational improvements as overshadowed by FDA and Health Canada setbacks, going concern language, Nasdaq noncompliance, and persistent control weaknesses, keeping risk elevated pending a successful De Novo resubmission.

Positives

• Revenue growth of 4.1% to $37.1 million with stronger distributor/partner and ex‑Germany direct sales.
• Gross margin expanded to 71.5% (from 69.9%), reflecting better mix and efficiencies.
• Operating loss improved to $14.7 million (from $16.5 million), aided by margin gains and lower R&D.
• R&D expense declined 33.2% to $5.1 million following STAR‑T completion and program reprioritization.
• Rights offering and warrant exercises added ~$7.0 million gross cash in 1H25; restricted cash covenant released $5 million.
• Loan amendment secured $2.5 million incremental debt and extended interest‑only to end‑2026, improving near‑term liquidity.
• Published multiple supportive real‑world registry analyses in 2025–2026 indicating potential clinical benefit in critical care and cardiac surgery applications.

Negatives

• Going concern uncertainty due to modest cash, historical burn (~$12.8 million 2025 operating+investing cash outflow), and reliance on external financing.
• FDA De Novo for DrugSorb‑ATR was denied (Apr 25, 2025) and denial was upheld on appeal (Aug 14, 2025), delaying U.S. commercialization.
• Health Canada issued a Notice of Refusal (Jun 26, 2025); Canadian pathway deferred pending FDA clarity.
• Nasdaq minimum bid price deficiency (notice on Oct 2, 2025) risks potential delisting without remediation.
• Material weaknesses in internal control over financial reporting persist (RSU accounting; 2025 consolidation and close process issues).
• SG&A rose 5% to $35.6 million despite restructuring; interest expense almost doubled to $2.6 million with higher debt load.
• Germany direct sales declined amid commercial realignment; PROCYSS trial paused; STAR‑D terminated.

Risks

• History of losses and potential need for additional capital; auditor raised substantial doubt about ability to continue as a going concern.
• Regulatory uncertainty: FDA De Novo denial for DrugSorb‑ATR (Apr 25, 2025) with resubmission pending; Health Canada Notice of Refusal (Jun 26, 2025).
• Nasdaq minimum bid price noncompliance (Oct 2, 2025) with a cure deadline of Mar 31, 2026 and potential need for a reverse stock split.
• Material weaknesses in internal controls (stock‑based compensation accounting; 2025 consolidation and close process).
• Reimbursement and market adoption risks across geographies; German hospital reform may change payment dynamics.
• Supply chain, pricing, and inflation pressures (labor, raw materials, energy, freight) could compress margins.
• Foreign currency volatility materially impacts results (large 2025 FX gain may not recur).
• Clinical program risks: PROCYSS paused; STAR‑D terminated; future studies may face delays or unfavorable outcomes.
• Debt covenants and higher interest burden may constrain flexibility; additional tranches contingent on FDA approval by Dec 31, 2026.
• Potential delisting if Nasdaq compliance is not regained; equity raises could be dilutive.

Future Outlook

Management plans to file a new De Novo for DrugSorb‑ATR following January 2026 FDA pre‑submission discussions, with a typical 150‑day review post‑submission; intends to re‑engage Health Canada after U.S. clarity and to pursue CMS TCET/NTAP pathways post‑authorization. The strategic cost program targets operating cash flow breakeven in the second half of 2026, while the Avenue Capital facility provides potential additional $2.5 million upon FDA approval by Dec 31, 2026.

Management Comments

• Target operating cash flow breakeven in H2 2026 following workforce and cost reductions.
• Will submit a new De Novo for DrugSorb‑ATR with additional real‑world data to support the desired CABG label.
• Believes DrugSorb‑ATR offers a strong value proposition and, upon approval, may benefit from TCET/NTAP reimbursement pathways.
• Plans to refile in Canada with improved FDA visibility and expand indications over time.
• Expects STAR Registry and COSMOS outputs to continue informing clinical practice and adoption.

Industry Context

StockSavvy.ai notes the hemoadsorption and blood purification space remains competitive (e.g., Baxter/Vantive Oxiris, Toray PMMA, Jafron HA330/380, Fresenius EMiC-2), but DrugSorb‑ATR targets a differentiated perioperative antithrombotic removal niche. The December 2025 U.S. withdrawal of Andexxa for DOAC reversal and bentracimab’s pending U.S. review could shift clinician preferences and payer calculus, potentially improving relative attractiveness of lower‑cost, device‑based solutions once authorized.

Comparison to Industry Standards

• Against large renal/critical care players (Fresenius, Baxter/Vantive), CytoSorbents’ $37 million revenue scale is small; however, a U.S. DrugSorb‑ATR approval would open a $300 million+ initial addressable market in CABG, with potential to exceed $1 billion as indications expand.
• Compared with biologic reversal agents (e.g., bentracimab for ticagrelor; Andexxa previously for DOACs), DrugSorb‑ATR’s device‑based approach may offer advantages in cost, procedural integration, and thrombotic safety profile for intraoperative use, per STAR‑T/STAR Registry publications.
• European adoption benchmarks: real‑world registry data (STAR, COSMOS) suggest favorable bleeding and critical care parameter trends aligned with EU practice, but inclusion in U.S. guidelines typically requires randomized evidence and FDA authorization.
• Gross margins at 71.5% compare favorably with medtech peers in disposables (often 60–70%), indicating scalable manufacturing economics if volume grows post‑approval.

Management Changes

Legal Proceedings

• Former employee CEPA claim filed Mar 5, 2024 in New Jersey was amicably resolved; no ongoing material litigation disclosed.

Related Party Transactions

• Management and Board members participated in the Jan 10, 2025 rights offering and some exercised Series A Rights Warrants on Feb 24, 2025.

Stakeholder Impact

• Shareholders face dilution risk from shelf/ATM usage and financing; Nasdaq bid deficiency raises delisting risk absent remediation.
• Employees impacted by ~10% workforce reduction tied to cost optimization.
• Customers and clinicians experience delayed U.S./Canada availability of DrugSorb‑ATR due to regulatory setbacks.
• Creditors benefit from amended loan terms and covenants but increased interest burden may pressure cash flows.
• Hospitals in Germany may see evolving reimbursement dynamics amid national hospital reform.

Next Steps

• Finalize requirements with FDA and file a new De Novo for DrugSorb‑ATR; anticipate a typical 150‑day review post‑submission.
• Refile with Health Canada after greater U.S. regulatory visibility.
• Pursue CMS TCET/NTAP pathways post‑authorization to support U.S. reimbursement.
• Execute the Strategic Workforce and Cost Reduction Plan to reach operating cash flow breakeven in H2 2026.
• Evaluate financing options (shelf/ATM/debt/royalty) as needed to support operations and regulatory milestones.
• Continue COSMOS/STAR Registry analyses and publications through 2026.

Key Dates

Recommendation

Balance the improved margins and narrowed loss against regulatory delays (FDA and Health Canada), going concern language, Nasdaq noncompliance, and control weaknesses. With a potential expedited De Novo path and optionality for additional financing, risk‑reward remains binary; a Hold is warranted pending clarity on the U.S. resubmission and liquidity trajectory.

Keywords

CytoSorbents, CTSO, DrugSorb-ATR, CytoSorb, FDA De Novo, cardiac surgery, ticagrelor removal, hemoadsorption, blood purification, EU CE Mark, MDSAP, Health Canada, rights offering, Nasdaq minimum bid, going concern, sepsis, ECOS-300CY, VetResQ, PuriFi, TCET